Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination with Second-line Therapy in Patients with Locally Advanced Unresectable, Recurrent and/ or Metastatic Hepatocellular Carcinoma

Principal Investigator: Iyer, Renuka V

(EA7222) A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas

Principal Investigator: Gupta, Ajay

A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors

Principal Investigator: Mukherjee, Sarbajit

Phase II Randomized, Double Blind, Placebo-Controlled Trial of the Broccoli Seed and Sprout Extract (BSSE), Avmacol ES, to Evaluate Sustained Detoxification of Tobacco Carcinogens in Heavy Smokers

Principal Investigator: Reid, Mary E

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

A phase 1b dose optimization study of sovilnesib (an oral KIF18A inhibitor) in subjects with advanced high grade serous ovarian cancer

Principal Investigator: McLean, Karen

(AALL2121) A Phase 2 study of revumenib (SNDX-5613) in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia

Principal Investigator: Mallhi, Kanwal

KOMEN-008: A Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Principal Investigator: Wang, Eunice S

B-Adrenergic Blockade with Chemotherapy and Checkpoint Inhibition in PD-L1
Positive Metastatic Triple Negative Breast Cancer

Principal Investigator: Gandhi, Shipra

Phase 1/2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma (RRMM)

Principal Investigator: Hillengass, Jens

A Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)

Principal Investigator: Niu, Alex

A Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced endometrial cancer

Principal Investigator: Mager, Katherine

(EAY191-N5): A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial

Principal Investigator: Levine, Ellis G

Phase II Study of Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 120]

Principal Investigator: Wang, Eunice S

A Phase I/II Study of Interstitial Photodynamic Therapy Following Palliative Radiotherapy for Patients with Inoperable Malignant Central Airway Obstruction

Principal Investigator: Ivanick, Nathaniel M

Phase II Trial of Carboplatin +/- Tocilizumab as Initial Therapy for Metastatic Triple Negative and ER-low Breast Cancers

Principal Investigator: Gandhi, Shipra

Utilizing Patient Reported Quality of Life to Inform Patient Decision Making In Early Stage Lung Cancer

Principal Investigator: Singh, Anurag K

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary
Efficacy of BMS-986393 in Novel Combinations in Participants with Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on…

Principal Investigator: Malek, Ehsan

A Phase 1, open label single-arm two-part study to investigate safety, pharmacokinetics, and preliminary efficacy of pan-RAF/MEK glue NST-628 oral tablets in subjects with solid tumors harboring genetic alterations in the MAPK pathway and with other…

Principal Investigator: Puzanov, Igor

( I-SPY 2) Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2

Principal Investigator: Levine, Ellis G

Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3

Principal Investigator: Bouchard, Elizabeth G

A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An fms-like tyrosine kinase 3 [FLT3] x cluster of differentiation 3 [CD3] bispecific T cell engager) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)…

Principal Investigator: Wang, Eunice S

IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR'S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2)

Principal Investigator: Switzer, Benjamin J

A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE
ESCALATION STUDY OF SGR-1505 AS
MONOTHERAPY IN SUBJECTS WITH MATURE B-CELL
MALIGNANCIES

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

A FIRST-IN-HUMAN PHASE 1/2 OPEN-LABEL STUDY OF INTRAVENOUS ST 067, SUBCUTANEOUS ST-067 WITH OR WITHOUT OBINUTUZUMAB PRE TREATMENT, AND ST-067 IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED SOLID MALIGNANCIES

Principal Investigator: Puzanov, Igor